Onset of Huntington's disease: Can it be purely cognitive?

Movement Disorders

Volumn 29, Issue 11, 2014, Pages 1342-1350

  Paulsen, Jane S ^a,b   Long, Jeffrey D ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Cognition; Diagnosis; Huntington's disease; Nonmotor; Onset

Indexed keywords

HTT PROTEIN, HUMAN; HUNTINGTIN; NERVE PROTEIN;

ADULT; COGNITIVE DEFECT; COMPLICATION; FEMALE; GENETICS; HUMAN; HUNTINGTON CHOREA; LONGITUDINAL STUDY; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; SEVERITY OF ILLNESS INDEX; TRINUCLEOTIDE REPEAT;

ADULT; COGNITION DISORDERS; FEMALE; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NEUROPSYCHOLOGICAL TESTS; SEVERITY OF ILLNESS INDEX; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84907927371     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25997     Document Type: Article

References (45)

1. Huntington G. On chorea. Med Surg Rep 1872;26:317-321.
2. Dumas EM, van den Bogaard SJ, Middelkoop HA, Roos RA. A review of cognition in Huntington's disease. Front Biosci (Schol Ed) 2013;5:1-18.
3. Stout JC, Paulsen JS, Queller S, et al. Neurocognitive signs in prodromal Huntington disease. Neuropsychology 2011;25:1-14.
4. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR, International Huntington's Disease Collaborative Group. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004;65:267-277.
5. Paulsen JS, Smith MM, Long JD, PREDICT-HD investigators and coordinators of the Huntington Study Group. Cognitive decline in prodromal Huntington disease: implications for clinical trials. J Neurol Neurosurg Psychiatry 2013;84:1233-1239.
6. Zhang Y, Long JD, Mills JA, et al. Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am J Med Genet B Neuropsychiatr Genet 2011;156B:751-763.
7. Verny C, Allain P, Prudean A, et al. Cognitive changes in asymptomatic carriers of the Huntington disease mutation gene. Eur J Neurol 2007;14:1344-1350.
8. Hahn-Barma V, Deweer B, Durr A, et al. Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers. J Neurol Neurosurg Psychiatry 1998;64:172-177.
9. Paulsen JS. Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep 2011;11:474-483.
10. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 2005;31:5-19.
11. Patrick DL, Burke LB, Powers JH, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 2007;10 Suppl 2:S125-137.
12. Vaccarino AL, Sills T, Anderson KE, et al. Assessment of cognitive symptoms in prodromal and early huntington disease. PLoS Curr 2011;3:RRN1250.
13. Vaccarino AL, Sills T, Anderson KE, et al. Assessment of day-to-day functioning in prodromal and early Huntington disease. PLoS Curr 2011;3:RRN1262.
14. Williams J, Downing N, Vaccarino AL, Guttman M, Paulsen JS. Self reports of day-to-day function in a small cohort of people with prodromal and early HD. PLoS Curr 2011;3:RRN1254.
15. Downing NR, Williams JK, Paulsen JS. Couples' attributions for work function changes in prodromal Huntington disease. J Genet Couns 2010;19:343-352.
16. Downing NR, Williams JK, Leserman AL, Paulsen JS. Couples' coping in prodromal Huntington disease: a mixed methods study. J Genet Couns 2012;21:662-670.
17. Penziner E, Williams JK, Erwin C, et al. Perceptions of discrimination among persons who have undergone predictive testing for Huntington's disease. Am J Med Genet B Neuropsychiatr Genet 2008;147:320-325.
18. Williams JK, Barnette JJ, Reed D, et al. Development of the Huntington disease family concerns and strategies survey from focus group data. J Nurs Meas 2010;18:83-99.
19. Williams JK, Erwin C, Juhl AR, et al. In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study. Am J Med Genet B Neuropsychiatr Genet 2010;153B:1150-1159.
20. Brandt J, Strauss ME, Larus J, Jensen B, Folstein SE, Folstein MF. Clinical correlates of dementia and disability in Huntington's disease. J Clin Neuropsychol 1984;6:401-412.
21. Harrington DL, Smith MM, Zhang Y, Carlozzi NE, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group. Cognitive domains that predict time to diagnosis in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 2012;83:612-619.
22. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology 2000;54:452-458.
23. Beglinger LJ, O'Rourke JJ, Wang C, et al. Earliest functional declines in Huntington disease. Psychiatry Res 2010;178:414-418.
24. Paulsen JS, Wang C, Duff K, et al. Challenges assessing clinical endpoints in early Huntington disease. Mov Disord 2010;25:2595-2603.
25. Aziz NA, Anguelova GV, Marinus J, Lammers GJ, Roos RA. Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington's disease. Parkinsonism Relat Disord 2010;16:345-350.
26. Helder DI, Kaptein AA, van Kempen GM, van Houwelingen JC, Roos RA. Impact of Huntington's disease on quality of life. Mov Disord 2001;16:325-330.
27. Banaszkiewicz K, Sitek EJ, Rudzinska M, Soltan W, Slawek J, Szczudlik A. Huntington's disease from the patient, caregiver and physician's perspectives: three sides of the same coin? J Neural Transm 2012;119:1361-1365.
28. Paulsen JS, Nance M, Kim JI, et al. A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases. Prog Neurobiol 2013;110:2-28.
29. Ready RE, Mathews M, Leserman A, Paulsen JS. Patient and caregiver quality of life in Huntington's disease. Mov Disord 2008;23:721-726.
30. Hamilton JM, Salmon DP, Corey-Bloom J, et al. Behavioural abnormalities contribute to functional decline in Huntington's disease. J Neurol Neurosurg Psychiatry 2003;74:120-122.
31. Nehl C, Paulsen JS, Huntington Study Group. Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity. J Nerv Ment Dis 2004;192:72-74.
32. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357-381.
33. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998;57:369-384.
34. Brooks SP, Dunnett SB. Cognitive deficits in animal models of basal ganglia disorders. Brain Res Bull 2013;92:29-40.
35. Fink KD, Rossignol J, Crane AT, et al. Early cognitive dysfunction in the HD 51 CAG transgenic rat model of Huntington's disease. Behav Neurosci 2012;126:479-487.
36. Giralt A, Puigdellivol M, Carreton O, et al. Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity. Hum Mol Genet 2012;21:1203-1216.
37. Harrison DJ, Busse M, Openshaw R, Rosser AE, Dunnett SB, Brooks SP. Exercise attenuates neuropathology and has greater benefit on cognitive than motor deficits in the R6/1 Huntington's disease mouse model. Exp Neurol 2013;248:457-469.
38. Duff K, Paulsen J, Mills J, et al. Mild cognitive impairment in prediagnosed Huntington disease. Neurology 2010;75:500-507.
39. Biglan KM, Zhang Y, Long JD, et al. Refining the diagnosis of Huntington disease: the PREDICT-HD study. Front Aging Neurosci 2013;5:12.
40. Paulsen JS, Long JD, Johnson HJ, et al. Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study. Front Aging Neurosci 2014;6:78.
41. Paulsen JS, Langbehn DR, Stout JC, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 2008;79:874-880.
42. Long JD, Paulsen JS, Marder K, et al. Tracking motor impairments in the progression of Huntington's disease. Mov Disord 2014;29:311-319.
43. O'Rourke JJ, Beglinger LJ, Smith MM, et al. The Trail Making Test in prodromal Huntington disease: contributions of disease progression to test performance. J Clin Exp Neuropsychol 2011;33:567-579.
44. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer, 2000.
45. Long JD, Paulsen JS, Marder K, et al. Tracking motor impairments in the progression of Huntington's disease. Mov Disord 2014;29:311-319.